Physician profile
Ryan M Bolt
NPI 1639679822
$4,652.79
in general payments reported to CMS, 2019-2025
25 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $1,247 · 2023: $786 · 2024: $991 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,222.81 | 2022-2025 | Caplyta |
| Lundbeck LLC | $623.69 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $472.29 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $449.07 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $291.03 | 2022-2025 | Auvelity |
| Abbvie INC. | $221.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $195.18 | 2021-2025 | Spravato |
| Neurocrine Biosciences, INC. | $144.38 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $132.78 | 2024-2025 | Rexulti |
| Harmony Biosciences LLC | $131.40 | 2024 | |
| Indivior INC. | $112.51 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $104.94 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $89.16 | 2022 | |
| Tactile Systems Technology INC | $72.71 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.68 | 2022-2023 | Austedo Xr, Uzedy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $59.33 | 2024 | |
| Glaxosmithkline, LLC. | $53.54 | 2023-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $48.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.50 | 2024 | Quviviq |
| Medtronic, INC. | $30.33 | 2024 | Intellis Adaptivestim |
| Hologic Sales and Service, LLC | $27.98 | 2025 | Aptima |
| Tris Pharma INC | $23.11 | 2024 | Dyanavel Xr |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Boston Scientific Corporation | $14.54 | 2021 | |
| Pfizer INC. | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bolt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.